Review Article

Circulating Nesfatin-1 Levels and Type 2 Diabetes: A Systematic Review and Meta-Analysis

Table 2

Summary risk estimates of circulating nesfatin-1 levels and type 2 diabetes mellitus.

StudiesRandom effects SMD (95% CI)I2 (%)P for heterogeneity

Overall7−0.16 (−0.57, 0.24)98<0.00001
Subgroup analysis
 Age
  <5530.00 (−0.41, 0.42)94<0.00001
  ≥554−0.08 (−0.53, 0.37)96<0.00001
 BMI
  <252−0.25 (−0.36, 0.13)0<0.0001
  ≥255−0.04 (−0.36, 0.44)96<0.00001
 HOMA-IR ratio
  <430.29 (−0.37, 0.95)98<0.00001
  ≥42−0.23 (−0.34, −0.12)00.91
  Unknown2−0.32 (−0.53, −0.11)330
Blood sample
  Plasma4−0.03 (−0.11, 0.05)00.98
  Serum3−0.24 (−0.33, −0.15)97<0.00001
 T2D criteria
  WHO40.16 (−0.31, 0.63)97<0.00001
  ADA3−0.26 (−0.36, −0.16)00.39
 Study type
  Case-control4−0.08 (−0.53, 0.37)96<0.00001
  Cross-sectional30.00 (−0.41, 0.41)94<0.00001
 Study quality
  Good6−0.01 (−0.35, 0.33)96<0.00001
  Moderate1